Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our Q1 2019 Report: Global Trends in Medtech Transactions applies the latest data to analyze current activities in the life sciences deal landscape. ​
​
In this report you can find an overview and analysis of the following medtech activities: ​

• Key performance indicators for the medtech market​​
• IPO and private financing activity and performance​​
• Deal activity for M&A​
• A look ahead and our predictions of the future 

HERE’S A SUMMARY OF KEY FINDINGS:

Q1 M&A activity represents a trend towards orthopedics and robotics ​

• M&A activity in Q1 focused on developing newer areas crucial to ongoing growth and health of the orthopedics and robotics sectors​
• Robotics, planning software, digital surgery, biodegradable implants, and non-drug, non-surgical treatments for pain draw the majority of the M&A and financing activity ​​

Capital from a broad spectrum of investors is supporting development and commercialization of surgical and diagnostic medical technologies ​

Medtech markets end Q1 at a high, with the industry demonstrating positive divergence from the S&P​

​Activities in digital health in Q1 indicate a rise of global medical technology​

• FDA piloting pre-cert program to allow developers who have been assessed by the FDA for meeting specific excellence principles to participate in a more tailored premarket submission process for their specific digital device ​
• The global orthopedist device market was valued at $38.7B in 2017, and is expected to reach $49.8B by the end of 2022 ​
• Despite the threat of cybersecurity issues related to digital technologies, investment by healthcare organizations in the space continues to grow